Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Three Energize program sponsors Takeda, Teva Pharmaceutical, and UCB, along with five industry suppliers, have signed a multi-buyer PPA with developers Zelestra and Bruc adding more than 280 MW of new ...

The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.

This funding boost will help Altamira progress their innovative pipeline while also supporting their ongoing divestment of legacy assets in allergology, viral infections, and inner ear disorders.

A U.S. appeals court has reinstated more than 500 lawsuits against drugmaker Merck & Co. because of its osteoporosis drug Fosamax, which plaintiffs allege increases risk of thigh bone fractures, ...

Fosamax was acquired in 2021 by Organon, which agreed to indemnify Merck against liability from the lawsuits. (Pierson, 9/20) Reuters: J&J Unit Files For Bankruptcy To Advance $10 Billion Talc ...

A dark-money group has launched a multi-state bus tour to bring awareness to what they characterize as bad behavior by pharma ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

At the heart of the event was Organon’s commitment to empowering women through access to safe and effective family planning ...

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...